TrialReader


Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers

NCT03413982 — Recruiting, 1000 participants, University of Kansas Medical Center

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT03413982, acronym GUB-BCR-001
StatusRecruiting
Study typeObservational
Enrollment1000 (Estimated)
SponsorUniversity of Kansas Medical Center (Other)
ConditionsBladder Cancer
InterventionsRegistry (Other)
Datesstart 2017-11-02, primary completion 2035-01-01 (estimated), completion 2035-01-01 (estimated), first posted 2018-01-29, last updated 2026-03-10
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Bladder Cancer All trials of Registry

-Summary

The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
BC PatientsOther: RegistryPatients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.
  • Registry (Other): Patient registry

+Outcome measures

Primary outcomes

  • Blood, urine and tissue characteristics of bladder cancer patients [24 months]: Samples will be collected over a 24 month period for patients to build a biorepository for future research on how they are related to tumor development, recurrence and survival.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate
* Patients can participate in any additional research studies during the patients' participation within this protocol.

Exclusion Criteria:

* Patients who do not have presumed bladder cancer will not be eligible

+Locations (1)

FacilityCityCountryStatus
University of Kansas Medical CenterKansas City, KansasUnited StatesRecruiting

+Investigators

  • John Taylor, MD, Principal investigator, University of Kansas Medical Center

My Notes